Kristin Stafford Biography and Net Worth

Director of NovoCure

Kristin Stafford became a director of Novocure in March 2023. She is currently Chief Financial Officer of Zymeworks Inc., a position she has held since April 2026. Prior to this she served as Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, from December 2018 and as Vice President, Finance of Royalty Pharma and Chief Financial Officer of BioPharma Credit plc, an affiliate of Royal Pharma, from 2016 to 2018. Ms. Stafford is a Certified Public Accountant and holds a bachelor of science degree in business administration from Sonoma State University.

What is Kristin Stafford's net worth?: The estimated net worth of Kristin Stafford is at least $182.88 thousand as of June 2nd, 2026. Ms. Stafford owns 11,324 shares of NovoCure stock worth more than $182,883 as of June 4th. This net worth approximation does not reflect any other assets that Ms. Stafford may own. Learn More about Kristin Stafford's net worth.
How do I contact Kristin Stafford?: The corporate mailing address for Ms. Stafford and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Kristin Stafford's contact information.
Has Kristin Stafford been buying or selling shares of NovoCure?: During the last quarter, Kristin Stafford has sold $46,442.65 in NovoCure stock. Most recently, Kristin Stafford sold 2,945 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a transaction totalling $46,442.65. Following the completion of the sale, the director now directly owns 11,324 shares of the company's stock, valued at $178,579.48. Learn More on Kristin Stafford's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Christoph Brackmann (CFO), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Allyson Ocean (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), Kristin Stafford (Director), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, NovoCure insiders bought shares 2 times. They purchased a total of 101,550 shares worth more than $1,228,341.00. During the last twelve months, insiders at the medical equipment provider sold shares 13 times. They sold a total of 157,711 shares worth more than $2,138,772.06. The most recent insider tranaction occured on June, 2nd when Director Gabriel Leung sold 2,945 shares worth more than $46,442.65. Insiders at NovoCure own 5.5% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 6/2/2026.

Kristin Stafford Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2026	Sell	2,945	$15.77	$46,442.65	11,324

Kristin Stafford Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $17.99

$16.23

$18.39

50 Day Range

MA: $14.16

$10.35

$18.31

2 Week Range

Now: $17.99

$9.82

$19.25

Volume

744,855 shs

Average Volume

1,764,437 shs

Market Capitalization

$2.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93